Where will NIB shares be in five years?

Is NIB a healthy opportunity right now?

Key points
  • NIB shares haven’t done much over the last five years, but I think the next five years are very promising
  • It’s wanting to capture a larger share of the NDIS market
  • The normalisation of COVID factors is helping both the travel insurance segment and international inbound segment

The NIB Holdings Limited (ASX: NHF) share price has only risen by 15% in the last five years. Could the next five years be a lot better for the private health provider?

One of the main things that have happened in the past five years is that NIB has diversified its sources of earnings.

The business has managed to grow its Australian resident policyholders at a much stronger rate than the wider industry over the long term. It also has other segments including 'international inbound health insurance', a New Zealand business and travel insurance.

There's one area in particular where the business thinks there is strong growth potential for the company to pounce on – the NDIS. NIB has a division called Thrive which it thinks has lots of potential.

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,

Image source: Getty Images

Significant marketplace

According to NIB and the NDIS quarterly report for June 2022, the NDIS 'marketplace' was worth $29 billion in FY22, with plan management and support co-ordination worth over $1 billion.

The company noted that it has long and deep experience in connecting buyers and sellers of healthcare, it's a well-known and trusted brand, and it has technology advantages.

NIB suggests that it has the capacity to lead orderly consolidation, improve efficiencies and integrity.

In the first half of FY23, it raised $158 million to make acquisitions in the NDIS space.

It has made four acquisitions. The first three came at a cost of $108 million with around 22,000 participants and annualised earnings before interest, tax, depreciation and amortisation (EBITDA) of $13.3 million.

It has also entered into an agreement to acquire plan manager All Disability Plan Management, based in Port Macquarie, which has about 3,000 participants.

The company said that it's considering further acquisitions.

NIB Thrive is expecting to manage plans for 50,000 NDIS participants by FY25. The ASX share said that the NDIS is expected to double in size by 2030, which may be a very positive sign for the NIB share price in the next five years and beyond.

Other aspects of the business are promising

With borders now open after COVID, the business is benefiting from the increased availability of travel. As more international travel occurs, I think this business will see improved earnings from higher volumes.

The international student volumes are strongly rebounding, while international workers are also adding to NIB's growth.

NIB is hoping to keep growing its policyholder numbers. Hospital claims are expected to remain subdued in the second half of FY23, though conditions (including margins) are expected to normalise as time goes on.

Is the NIB share price good value?

According to estimates on Commsec, NIB could generate 43.2 cents of EPS in FY25. This would put NIB shares at under 17 times FY25's estimated earnings. I think that's a reasonable valuation considering the business is expected to grow both its EPS and dividend in each of the next few years.

I think it can keep growing its policyholders and profit, making it an attractive option for the next five years and perhaps beyond.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »